Company release, inside information

12 April 2024 at 7.15 a.m. (EEST)

Nightingale Health has entered into an agreement with Kaiser Foundation Health Plan, Inc. to analyze 50,000 blood samples from the Kaiser Permanente Research Bank. As part of the agreement, Nightingale Health will analyze the 50,000 blood samples with its proprietary technology and deliver the blood biomarker data to the Kaiser Permanente Research Bank.

Kaiser Foundation Health Plan, Inc. together with Kaiser Foundation Hospitals and its subsidiaries and the Permanente Medical Groups, form one of the largest integrated healthcare consortiums in the United States. The Kaiser Permanente Research Bank is one of the largest biobanks in the United States.

At the core of Nightingale Health’s strategy is to bring the company’s proprietary blood analysis technology to healthcare use globally by first demonstrating its clinical utility in large biobank sample collections. These collections provide the scientific evidence base required for translation and large-scale population-level clinical use.

Nightingale Health has already successfully executed its strategy in Europe where it has made available to researchers the analysis results from 500,000 blood samples via UK Biobank and started the first large-scale clinical implementation with Finland’s largest private healthcare provider, Terveystalo. Terveystalo has replaced clinical chemistry tools with Nightingale Health’s biomarkers and risk prediction models in routinely performed health checks which cover approximately 30% of the Finnish working population.

Analyzing the samples from the Kaiser Permanente Research Bank will start by the end of June 2024.

For further information, please contact:

Teemu Suna, CEO

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 530 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: